Sources and References

Primary textbook — Bilezikian, J.P., Martin, T.J., Insogna, K.L., & Peacock, M. (Eds.) (2021). The Parathyroids: Basic and Clinical Concepts, 4th Edition. Academic Press. American College of Sports Medicine (ACSM). Clinical Exercise Physiology, 4th Edition. Lippincott Williams & Wilkins.

Supplementary texts — Favus, M.J. (Ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th Edition. ASBMR. Kelley, G., & Kelley, K.S. (Eds.). Exercise, Arthritis, and Aging. Springer.

Online resources — Osteoporosis Canada (osteoporosis.ca); Arthritis Society Canada (arthritis.ca); The Bone and Joint Decade (boneandjointdecade.org); American College of Rheumatology (rheumatology.org); UpToDate clinical guidelines; PubMed (pubmed.ncbi.nlm.nih.gov); Journal of Bone and Mineral Research; Arthritis & Rheumatology; Osteoporosis International.

Chapter 1: Bone Composition and Structure

What Is Bone Made Of?

Bone is a living, metabolically active composite material — simultaneously a structural organ that protects vital organs and provides mechanical support for locomotion, a mineral reservoir that supplies calcium and phosphate to maintain the ionic composition of blood and extracellular fluid, a hematopoietic organ (in the marrow spaces of cancellous bone) that produces all blood cells, and an endocrine organ that secretes hormones (osteocalcin, FGF-23, sclerostin) with systemic effects on glucose metabolism, kidney function, and muscle. Understanding each of these functions is necessary for understanding the full clinical consequences of bone disease.

At the compositional level, bone consists of two primary phases: an organic matrix (approximately 30–35% of dry mass) and an inorganic mineral phase (approximately 65–70% of dry mass). The organic matrix is dominated by type I collagen (comprising approximately 90% of the organic matrix), a fibrillar protein assembled from two alpha-1 chains and one alpha-2 chain that coil together in a right-handed triple helix — the most abundant structural protein in the body. Type I collagen fibrils are stabilized by enzymatic cross-links formed by lysyl oxidase between specific lysine and hydroxylysine residues, and the pattern of cross-linking (immature divalent cross-links early in maturation, mature trivalent cross-links with age) profoundly affects bone toughness. Non-enzymatic glycation of collagen (producing advanced glycation end-products, AGEs — particularly pentosidine) accumulates with age and disease, reducing the energy needed to propagate cracks through bone and contributing to the increased fracture risk associated with diabetes independently of bone mineral density.

The non-collagenous proteins of bone matrix — including osteocalcin, osteopontin, bone sialoprotein, osteonectin/SPARC, and various proteoglycans — are quantitatively minor but functionally important. Osteocalcin is the most abundant non-collagenous bone matrix protein, produced exclusively by osteoblasts, and contains three gamma-carboxyglutamate (Gla) residues that bind calcium and mediate its association with the hydroxyapatite mineral phase — a process requiring vitamin K as the cofactor for carboxylation. Undercarboxylated osteocalcin is released into the circulation and acts as an endocrine hormone: it stimulates pancreatic beta-cell proliferation and insulin secretion, enhances muscle glucose uptake during exercise, and — in rodent models — has been shown to partially mediate the metabolic and cognitive benefits of exercise, though the human physiology of osteocalcin as an exercise hormone is an area of active research.

The inorganic mineral phase consists primarily of carbonated hydroxyapatite crystals — nanosized (approximately 20 × 40 × 5 nm), plate-like crystals deposited preferentially within and between the gap regions of collagen fibrils in a specific crystallographic orientation that aligns the crystal’s c-axis with the collagen fiber long axis. This co-alignment of mineral and collagen creates a nanocomposite with mechanical properties superior to either constituent alone — a principle exploited in the design of bio-inspired engineering materials. The composition of the mineral phase is not static: carbonation of the apatite lattice (replacement of phosphate by carbonate) reduces crystal crystallinity and increases solubility, making younger bone mineral more soluble and biologically reactive than older, more crystalline mineral. The “ion substitution” approach of fluoride treatment for osteoporosis (which partially replaces hydroxyl ions with fluoride, forming fluorapatite that is much less soluble than hydroxyapatite) is based on this principle, though its clinical utility is limited by concerns about fluorapatite’s reduced toughness.

How Does Bone Turnover Work and What Cells Are Involved?

Bone remodeling occurs at discrete anatomical sites called basic multicellular units (BMUs), which are self-contained remodeling units consisting of an osteoclast cutting cone (or resorption lacuna on trabecular surfaces) followed by a refilling zone of osteoblasts. A single remodeling cycle takes approximately 3–4 months: osteoclasts resorb bone over 2–4 weeks, followed by a reversal phase in which coupling signals are released from the resorbed matrix, followed by osteoblastic bone formation over 2–3 months. The cellular biology of each cell type in the BMU reflects its specialized function.

Osteoclasts are the bone-resorbing cells, derived from the monocyte-macrophage lineage of hematopoietic precursors. They are polarized cells: the surface facing the bone (the ruffled border) is extensively folded to maximize the resorptive surface area and is enclosed by a specialized zone of tight cytoskeletal attachment to bone (the sealing zone, created by circumferential podosomes containing F-actin, vinculin, paxillin, and the alpha-v-beta-3 integrin bound to the bone matrix protein osteopontin). The sealed compartment beneath the ruffled border is acidified to pH 4–5 by the vacuolar H+-ATPase (V-ATPase) on the ruffled border membrane and by carbonic anhydrase II (which generates protons from CO2 and H2O); the acidic environment dissolves the hydroxyapatite mineral phase, releasing calcium and phosphate. The organic matrix is simultaneously degraded by cathepsin K — a cysteine protease secreted by osteoclasts that cleaves collagen at the acidic pH of the resorption lacuna. Cathepsin K is the drug target of odanacatib (a cathepsin K inhibitor that reduced fracture risk in clinical trials but was discontinued due to increased stroke risk).

Osteoblasts are the bone-forming cells, derived from mesenchymal stem cells (MSCs, also called bone marrow stromal cells) that can also differentiate into adipocytes, chondrocytes, fibroblasts, and muscle cells — a lineage hierarchy with important implications for age-related changes in bone (where the balance between osteoblast and adipocyte differentiation shifts toward adipogenesis, explaining the increased marrow adiposity of aging bone). Osteoblasts synthesize and secrete type I collagen (which assembles into the organic matrix or osteoid), and they direct the process of mineralization by secreting matrix vesicles (lipid-enclosed structures that concentrate calcium and phosphate and nucleate the first mineral crystals), by expressing PHOSPHO1 (which generates phosphate within matrix vesicles), and by expressing alkaline phosphatase (which cleaves pyrophosphate — an inhibitor of mineralization — and thereby permits hydroxyapatite crystallization). Osteoblasts also control osteoclast differentiation through the RANK/RANKL/OPG system — the critical molecular system governing the coupling of bone resorption and formation.

The RANK/RANKL/OPG System

The RANK/RANKL/OPG axis is the central molecular system controlling osteoclastogenesis and is the most therapeutically important pathway in bone biology, being the target of the anti-fracture drug denosumab (one of the most widely used drugs for osteoporosis management).

RANKL (Receptor Activator of NF-κB Ligand, also known as TRANCE, ODF, or OPGL) is a TNF superfamily member expressed on the surface of osteoblasts, osteocytes, and bone marrow stromal cells. It binds to its receptor RANK (Receptor Activator of NF-κB) on the surface of osteoclast precursors (monocyte-macrophage lineage cells), triggering the dimerization of RANK and recruitment of TRAF6 (TNF receptor-associated factor 6), which activates downstream signaling cascades including NF-κB, MAPK (ERK, JNK, p38), and PI3K/Akt. These cascades collectively drive the expression of the osteoclast master transcription factor NFATc1 (nuclear factor of activated T cells, cytoplasmic 1), which drives the transcription of all the genes required for osteoclast differentiation and function: cathepsin K, calcitonin receptor, TRAP (tartrate-resistant acid phosphatase), the V-ATPase subunit, and the integrin alpha-v-beta-3. M-CSF (macrophage colony-stimulating factor, also called CSF1), produced by osteoblasts and stromal cells, provides an essential survival and proliferation signal for osteoclast precursors that is required alongside RANKL for osteoclastogenesis to proceed.

OPG (Osteoprotegerin) is a soluble decoy receptor for RANKL — a secreted TNF receptor family member (produced by osteoblasts and many other cell types) that binds RANKL with high affinity and competitively inhibits its binding to RANK, thereby suppressing osteoclastogenesis. The RANKL/OPG ratio — the relative abundance of the stimulatory ligand versus the inhibitory decoy receptor — is the key determinant of osteoclast activity and therefore of the rate of bone resorption. Conditions that increase the RANKL/OPG ratio (estrogen deficiency post-menopause, glucocorticoid excess, inflammatory cytokines including TNF-alpha and IL-1 in rheumatoid arthritis, PTH elevation in hyperparathyroidism, vitamin D deficiency) increase osteoclast activity and bone resorption. Denosumab is a fully human monoclonal antibody that binds RANKL with high affinity, mimicking the action of OPG and suppressing osteoclastogenesis — producing potent, rapidly reversible suppression of bone resorption and significant reduction in vertebral, hip, and non-vertebral fracture risk.

Wnt Signaling in Bone Formation

The Wnt/beta-catenin signaling pathway is the primary anabolic pathway in bone — the molecular system through which mechanical loading, parathyroid hormone (given intermittently), and the drug romosozumab stimulate bone formation. Understanding Wnt signaling in bone is essential for understanding both the biology of bone adaptation to exercise and the pharmacology of anabolic osteoporosis drugs.

In the canonical Wnt pathway, binding of Wnt ligands (a family of 19 secreted glycoproteins in humans) to the co-receptor complex of Frizzled (Fzd, a seven-pass transmembrane receptor) and LRP5 or LRP6 (low-density lipoprotein receptor-related protein 5 or 6) inhibits the destruction complex — a multiprotein complex (consisting of Axin, APC, GSK3-beta, and CK1) that normally phosphorylates beta-catenin, marking it for ubiquitination and proteasomal degradation. Stabilized beta-catenin accumulates in the cytoplasm and translocates to the nucleus, where it co-activates TCF/LEF transcription factors to drive target gene expression. In osteoblasts, Wnt/beta-catenin target genes include those promoting osteoblast differentiation (Runx2, Osterix), osteoblast survival (anti-apoptotic Bcl-2 family members), and OPG (thereby simultaneously suppressing osteoclast activity).

The importance of LRP5 for bone mass was dramatically revealed by the discovery that high bone mass (HBM) syndrome — an autosomal dominant condition characterized by exceptional bone mineral density without adverse effects — is caused by gain-of-function mutations in LRP5 that prevent binding of the endogenous Wnt inhibitor DKK1 (Dickkopf 1). Conversely, loss-of-function mutations in LRP5 cause osteoporosis-pseudoglioma syndrome — a rare autosomal recessive condition combining severe osteoporosis with congenital or childhood-onset blindness. These human genetic experiments established Wnt signaling through LRP5 as a major determinant of bone mineral density and a compelling therapeutic target.

Sclerostin (encoded by the SOST gene) is perhaps the most important endogenous Wnt antagonist in bone. It is produced exclusively by osteocytes — the terminally differentiated osteoblasts embedded in the bone matrix — and acts as a negative feedback regulator of bone formation: sclerostin binds to LRP5/6 and inhibits Wnt signaling, suppressing osteoblast activity. Mechanical loading of bone suppresses sclerostin expression in osteocytes (through a mechanism involving cyclic AMP, prostaglandins, and the mechanosensory function of osteocyte primary cilia), thereby releasing the Wnt pathway from inhibition and promoting bone formation in loaded regions. This is the molecular mechanism underlying Wolff’s Law — bone adapts its architecture to the mechanical demands placed upon it — and explains why weight-bearing exercise promotes bone formation while unloading causes bone loss. The drug romosozumab (Evenity) is a monoclonal antibody that neutralizes sclerostin, producing a dramatic increase in bone formation (measured by bone formation markers such as P1NP) simultaneously with a moderate reduction in bone resorption — making it a dual-action agent with the strongest anti-fracture efficacy of currently available osteoporosis therapies.

Chapter 2: Bone Growth, Development, and Aging

How Bone Grows and Develops

Bone development occurs through two distinct processes: intramembranous ossification (in which bone is formed directly within a membrane of connective tissue, without a cartilage intermediate — the mechanism by which flat bones of the skull, clavicle, and mandible form) and endochondral ossification (in which a hyaline cartilage model is progressively replaced by bone — the mechanism by which long bones, vertebrae, and ribs form). Endochondral ossification is the process relevant to the longitudinal growth of the limbs and axial skeleton, and understanding it is prerequisite to understanding growth disorders and growth plate physiology.

In endochondral ossification, a cartilage anlage is established by condensation of mesenchymal cells and their differentiation to chondrocytes. The cartilage model grows by both interstitial growth (chondrocyte proliferation within the model) and appositional growth (from the perichondrium). The growth plate (physis) is the specialized region of cartilage responsible for longitudinal bone growth; it is organized into distinct histological zones from the epiphysis (joint end) to the metaphysis (shaft end): the reserve zone (quiescent chondrocytes above the proliferative zone), the proliferative zone (columnar, rapidly dividing chondrocytes oriented along the longitudinal axis), the hypertrophic zone (chondrocytes that undergo a massive increase in cell volume), and the zone of calcified cartilage (where the hypertrophic chondrocytes die by a process resembling apoptosis, the cartilage matrix becomes calcified, and blood vessels and osteoblasts invade from the metaphysis to begin primary ossification). The rate of longitudinal growth is determined by the rate of chondrocyte proliferation and the size of the hypertrophic increase in each chondrocyte, which are regulated by the interplay of Indian hedgehog (Ihh) and PTHrP (parathyroid hormone-related protein) in a negative feedback loop that coordinates growth plate dynamics.

Bone elongation ceases at the end of puberty when sex hormones (particularly estrogens, acting through estrogen receptor alpha on growth plate chondrocytes in both sexes) drive the terminal differentiation and apoptosis of the remaining growth plate chondrocytes, producing growth plate fusion — the replacement of the growth plate by bone (the epiphyseal line) and the permanent cessation of longitudinal growth. The timing of growth plate fusion is sex-hormone dependent, which explains why boys, who have delayed and lower estrogen exposure compared to girls, continue to grow for approximately 2 years longer than girls after the onset of puberty — reaching a final adult height that is, on average, approximately 13 cm taller.

Peak Bone Mass and Bone Mass Across the Lifespan

Peak bone mass — the maximum amount of bone mineral density and bone mass achieved during the lifespan — is attained in the late second to early third decade of life, with timing varying by skeletal site and sex. The magnitude of peak bone mass is the single most important determinant of lifetime fracture risk: individuals who achieve a higher peak bone mass have a greater reserve to accommodate the inevitable age-related bone loss before reaching the fracture threshold. Genetic factors account for approximately 60–80% of the variance in peak bone mass (primarily through variants affecting the Wnt pathway, RANK/RANKL, and vitamin D receptor function), while modifiable factors — nutrition (calcium and vitamin D), physical activity (particularly weight-bearing and high-impact exercise during childhood and adolescence), sex hormone status, and body mass — account for the remainder.

Approximately 25–40% of peak bone mass is accumulated during the pubertal growth spurt (approximately ages 11–13 in girls and 13–15 in boys), making nutrition and exercise during this developmental window of critical importance for lifelong skeletal health. This makes adolescent nutrition interventions — ensuring adequate calcium (1,300 mg/day) and vitamin D (600 IU/day), encouraging vigorous weight-bearing physical activity — a primary prevention strategy for osteoporosis decades later. After peak bone mass is achieved, bone mass remains relatively stable through the third and fourth decades, then begins to decline from approximately age 40 in both sexes. The rate of decline accelerates dramatically in women in the early postmenopausal period (1–3% per year in trabecular bone) due to estrogen withdrawal, then slows to approximately 0.5–1% per year in the later postmenopausal period. Men experience slower and more linear bone loss, without the dramatic acceleration associated with menopause, but eventually reach the fracture threshold at older ages.

Microcrack Accumulation and Bone Fatigue

Real bone in vivo is subjected to millions of loading cycles per year during normal activities, and the resulting fatigue loading progressively accumulates microscopic damage in the form of microcracks — typically 50–200 μm long linear cracks propagating through the bone matrix. Microcracks accumulate preferentially at regions of stress concentration (including cement lines between osteons and at the tips of existing cracks) and at the boundaries between different tissue types (cortical-cancellous interfaces). The progressive accumulation of microdamage would eventually lead to catastrophic failure (stress fracture) if not prevented by bone remodeling: targeted remodeling to damaged areas removes microcracked bone and replaces it with new, undamaged bone — a quality control mechanism that requires intact osteocyte mechanosensing.

Osteocytes — terminally differentiated osteoblasts embedded in lacunae within the mineralized matrix, connected to each other and to surface cells by a network of cytoplasmic processes running through nanoscale canaliculi — are the primary mechanosensors of bone. They detect microdamage through two mechanisms: disruption of the pericellular fluid flow in canaliculi (which is altered by cracks that cross canalicular channels), sensed by primary cilia and stretch-activated ion channels; and disruption of the dendritic processes of osteocytes themselves by propagating cracks. Damaged or apoptotic osteocytes send pro-remodeling signals to surface cells — primarily by reducing sclerostin secretion (thereby releasing the Wnt brake on osteoblasts) and by increasing RANKL expression (recruiting osteoclasts to the damaged area). The extraordinary specificity of targeted remodeling — which must activate remodeling precisely at the site of microdamage among the entire skeletal volume — requires that osteocytes function as both damage detectors and signal transducers.

Chapter 3: Factors Affecting Bone Strength

Hormonal Regulation of Calcium and Bone Remodeling

The skeletal system is exquisitely regulated by a hormonal network that maintains serum calcium concentration within a narrow range while also governing bone remodeling rates. The three principal regulators are parathyroid hormone (PTH), 1,25-dihydroxyvitamin D (calcitriol), and calcitonin, with important modulatory roles for sex hormones, glucocorticoids, thyroid hormones, growth hormone/IGF-1, and the more recently discovered FGF-23.

Parathyroid hormone (84 amino acid peptide from the chief cells of the four parathyroid glands) is the primary acute regulator of serum calcium. It is secreted in response to a fall in ionized calcium, sensed by the calcium-sensing receptor (CaSR) on parathyroid chief cells. PTH acts on three target tissues: kidney (increasing calcium reabsorption in the distal nephron and stimulating 1-alpha-hydroxylase to produce calcitriol), intestine (indirectly, by stimulating calcitriol production, which increases intestinal calcium absorption), and bone (stimulating bone resorption through indirect osteoclast activation — PTH receptor is expressed on osteoblasts and osteocytes, not osteoclasts; PTH stimulates osteoblastic RANKL expression and suppresses OPG, increasing the RANKL/OPG ratio and thus osteoclast activity). The net effect is to raise serum calcium. In primary hyperparathyroidism — adenoma or hyperplasia of the parathyroid glands causing autonomous PTH excess — chronically elevated PTH produces hypercalcemia and skeletal effects including subperiosteal bone resorption (particularly in cortical bone), osteitis fibrosa cystica (in severe cases), and decreased bone mineral density.

Paradoxically, intermittent PTH administered subcutaneously (teriparatide, the N-terminal 1-34 fragment of PTH; abaloparatide, a PTHrP analogue) is a potent anabolic bone treatment, activating bone formation more than resorption when given as a once-daily injection. The anabolic versus catabolic effects of PTH on bone depend critically on the temporal pattern of exposure: continuous elevated PTH favors resorption, while brief, pulsatile increases in PTH favor formation. The molecular basis of this difference is still not fully elucidated but may involve differential activation of downstream signaling cascades (cAMP/PKA, PKC, MAPK) by sustained versus pulsatile receptor occupancy, and differential regulation of sclerostin (pulsatile PTH dramatically suppresses sclerostin, releasing the Wnt brake on osteoblasts).

Gonadal Steroids and Bone

The importance of sex hormones to skeletal homeostasis is perhaps most dramatically illustrated by the accelerated bone loss that follows estrogen withdrawal at menopause — a biological experiment that Nature performs on approximately 50% of the population. Estrogen’s protective effects on bone are mediated primarily through estrogen receptor alpha (ERα), expressed in osteoblasts, osteoclasts, and osteocytes. In osteoclasts, ERα activation promotes apoptosis (through Fas ligand-mediated cell death) and reduces RANK signaling sensitivity. In osteoblasts, estrogen promotes survival and increases OPG expression relative to RANKL. In osteocytes, estrogen increases mechanosensitivity, enabling the mechanostat to better detect and respond to loading. The consequence of estrogen deficiency is a dramatic increase in the RANKL/OPG ratio, greatly accelerating osteoclast-mediated bone resorption, with bone formation unable to keep pace — producing the net bone loss of postmenopausal osteoporosis.

Testosterone is also critical for skeletal homeostasis in males, though its mechanism is more complex: much of testosterone’s skeletal effect is mediated by aromatization to estradiol (particularly in osteoblasts and osteocytes, which express aromatase), explaining why estrogen deficiency is also relevant in males (late-onset hypogonadism, aromatase deficiency). Direct androgen receptor (AR) signaling in bone primarily promotes periosteal apposition — the outward expansion of bone that contributes to the greater bone diameter and thus greater bending strength of male versus female bone. Males with inactivating mutations in the AR (complete androgen insensitivity syndrome, CAIS) or in aromatase (aromatase deficiency) have markedly reduced bone mineral density, confirming the roles of both androgen receptor and estrogen receptor signaling in male skeletal homeostasis.

Stress fractures are the canonical overuse injury of bone, occurring when cumulative fatigue damage exceeds the bone’s ability to repair through targeted remodeling. They occur most commonly in the metatarsals, tibia (particularly the medial aspect), fibula, navicular, and femoral neck in runners and military recruits, and in the pars interarticularis of the lumbar spine in gymnasts and fast bowlers. Risk factors include rapid increases in training volume or intensity, poor technique, inadequate nutrition (particularly low energy availability and low calcium and vitamin D), hormonal abnormalities (the female athlete triad — low energy availability, menstrual disturbance, low bone density — and its broader form, Relative Energy Deficiency in Sport, RED-S), and intrinsic biomechanical factors (limb length discrepancy, foot pronation/supination abnormalities, tibial varum). The clinical presentation of a stress fracture — gradual onset of well-localized bone tenderness with insidious exertional pain that worsens with loading — should prompt imaging; plain X-ray is insensitive in the early stages, and MRI or bone scan is preferred for early diagnosis.

Physical Activity and Bone Health

The skeletal response to mechanical loading is governed by a mechanostat model (proposed by Harold Frost), in which bone mass and architecture are regulated to maintain tissue-level strains within a target range (the “setpoint”). Strains chronically below the setpoint (as in immobilization or microgravity) activate remodeling that removes bone until the remaining structure experiences strains at or above the setpoint from habitual loads. Strains chronically above the setpoint (as in vigorous weight-bearing exercise) activate modeling (new bone deposition on periosteal surfaces) until the enlarged structure experiences strains within the setpoint range. The molecular executor of this mechanostat is the osteocyte, which senses matrix strain (and associated pericellular fluid flow and hydrostatic pressure changes) and adjusts sclerostin and RANKL/OPG secretion accordingly.

The characteristics of osteogenic exercise have been systematically investigated in both animal and human studies. High impact activities — those generating high peak forces on bone and high rates of force application — are most osteogenic, because both peak strain and strain rate are the primary determinants of osteocyte mechanosensing and bone formation response. Jumping, gymnastics, impact aerobics, and running generate greater osteogenic stimuli than swimming, cycling, or resistance training without an impact component. Diverse loading patterns — varying the direction of loading across multiple planes — are more osteogenic than monotonous loading in a single direction, because bone adapts specifically to habitual loading directions and becomes less responsive to repeated identical stimuli (habituation). Progressive loading — gradually increasing the challenge as bone adapts — is necessary for ongoing stimulus, consistent with the training principle of progressive overload.

Chapter 4: Osteoporosis

Definition, Epidemiology, and Risk Factors

Osteoporosis is a major public health problem of extraordinary scale. In Canada, approximately 2 million individuals have osteoporosis and a further 2.2 million have osteopenia. One in three women and one in five men over 50 will suffer an osteoporotic fracture in their lifetime. The clinical consequences of fragility fracture are severe: hip fractures carry a 30-day mortality of approximately 5–10% and one-year mortality of approximately 20–30%; approximately 50% of hip fracture survivors do not return to their pre-fracture level of function; and the annual healthcare cost of osteoporotic fractures in Canada exceeds $4 billion. Vertebral compression fractures — the most prevalent osteoporotic fracture — cause chronic pain, height loss, kyphosis (Dowager’s hump), reduced lung capacity, and impaired quality of life. Wrist (distal radius, Colles’) fractures are common but less immediately life-threatening, yet they signal significantly elevated risk of subsequent vertebral and hip fracture.

Risk factors for osteoporosis and fragility fracture span genetic, hormonal, nutritional, lifestyle, and medication-related domains. The most clinically important risk factors for fracture include: prior fragility fracture (which doubles subsequent fracture risk independently of BMD — fracture begets fracture through a combination of bone fragility, fear of falling, impaired functional capacity, and associated muscle weakness); advanced age; female sex; low BMD; glucocorticoid use (systemic glucocorticoids at doses equivalent to prednisolone ≥ 2.5–5 mg/day for 3 or more months impair bone formation through FoxO-mediated osteoblast apoptosis and directly suppress the HPA axis governing gonadal steroid production, causing rapid and substantial bone loss — glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis); low body weight (BMI below 20 kg/m²); family history of osteoporosis or hip fracture in a parent; smoking; excessive alcohol consumption; and secondary causes including rheumatoid arthritis, inflammatory bowel disease, celiac disease, chronic kidney disease, and hypogonadism.

Fracture Risk Assessment and DXA

The clinical assessment of fracture risk integrates BMD measurement with clinical risk factors using validated fracture risk calculators. The most widely used is the FRAX tool (www.shef.ac.uk/FRAX), developed by the WHO, which uses BMD and up to 12 clinical risk factors to calculate the 10-year probability of major osteoporotic fracture (hip, clinical spine, proximal humerus, and distal forearm) and hip fracture specifically. FRAX outputs are used to stratify patients into treatment decision categories in many national guidelines, including Osteoporosis Canada’s 2023 clinical practice guidelines.

Dual-energy X-ray absorptiometry (DXA) is the gold standard clinical tool for measuring BMD and forms the basis of the WHO T-score definition of osteoporosis. DXA uses two X-ray beams at different energy levels to discriminate between bone and soft tissue, measuring the areal bone mineral density (aBMD, in g/cm²) at the lumbar spine (L1-L4), total proximal femur (total hip), and femoral neck. The T-score expresses the individual’s BMD relative to the mean of a young adult (peak bone mass) reference population of the same sex; the Z-score expresses it relative to an age-, sex-, and ethnicity-matched reference population. The T-score is used for fracture risk assessment in postmenopausal women and men over 50; the Z-score is used for younger individuals and children, where comparison to age-matched rather than peak-bone-mass references is appropriate.

DXA also provides measures beyond simple BMD that add clinical information: vertebral fracture assessment (VFA), a lateral spine imaging protocol that identifies prevalent vertebral fractures (which are asymptomatic in approximately 65% of cases but substantially increase subsequent fracture risk); trabecular bone score (TBS), a texture measure derived from the lumbar spine DXA image that provides information about trabecular microarchitecture independent of BMD (lower TBS indicates more deteriorated microarchitecture); and body composition measures (lean mass, fat mass, bone mineral content in compartments) that are valuable for monitoring sarcopenia and obesity interventions. High-resolution peripheral quantitative computed tomography (HR-pQCT) is a research tool that images the distal radius and distal tibia at approximately 60–80 μm voxel resolution, providing detailed measures of cortical and trabecular microarchitecture and finite element analysis-derived bone strength estimates — information that substantially improves fracture risk prediction beyond DXA but is currently available only at specialized research centers.

Osteoporosis Management: Pharmacological Treatment

The clinical management of osteoporosis combines lifestyle interventions (exercise, nutrition) with pharmacological treatment in individuals at high fracture risk. Pharmacological agents are classified as anti-resorptive (suppressing osteoclast activity) or anabolic (stimulating osteoblast bone formation).

Bisphosphonates are the first-line pharmacological treatment for most patients. They are pyrophosphate analogues with high affinity for bone mineral that accumulate in bone at sites of active remodeling and are endocytosed by osteoclasts, where they inhibit farnesyl pyrophosphate synthase (FPPS) — an enzyme in the mevalonate/cholesterol biosynthetic pathway. FPPS inhibition reduces the prenylation of small GTPases (Ras, Rho, Rac) required for osteoclast cytoskeletal organization and survival, inducing osteoclast apoptosis. Commonly used bisphosphonates include alendronate (weekly oral), risedronate (weekly or monthly oral), and zoledronic acid (annual intravenous infusion). Meta-analyses confirm that bisphosphonates reduce vertebral fracture risk by approximately 40–50%, hip fracture risk by approximately 25–40%, and non-vertebral fracture risk by approximately 20–30%. Major concerns with long-term bisphosphonate use include atypical femoral fractures (rare, occurring with prolonged use — estimated at 3–5 per 10,000 patient-years after 5 years of use) and osteonecrosis of the jaw (ONJ) (predominantly a risk in patients receiving high-dose IV bisphosphonates for cancer treatment, rare with oral doses used for osteoporosis).

Denosumab (Prolia), 60 mg subcutaneously every 6 months, is a monoclonal antibody targeting RANKL that suppresses osteoclast formation with potency exceeding that of bisphosphonates. It reduces vertebral fracture risk by approximately 68%, hip fracture risk by 40%, and non-vertebral fracture risk by 20% in the FREEDOM trial. Unlike bisphosphonates, denosumab does not accumulate in bone — it is cleared by normal antibody catabolism — and stopping denosumab abruptly produces a dramatic rebound increase in bone resorption (due to the restoration of unbound RANKL) that can result in multiple vertebral fractures within 12–24 months of discontinuation. Patients who must stop denosumab should transition to a bisphosphonate to suppress the rebound.

Teriparatide (Forteo, PTH 1-34, subcutaneous daily injection) and abaloparatide (Tymlos, PTHrP analogue, subcutaneous daily injection) are anabolic agents that stimulate bone formation predominantly, reducing vertebral fracture risk by approximately 65–86% and non-vertebral fracture risk by approximately 50% in randomized trials. Romosozumab (Evenity, anti-sclerostin antibody, monthly subcutaneous injection) has dual action: it stimulates bone formation (through Wnt pathway release) and suppresses bone resorption (through mechanisms including osteocyte RANKL suppression), producing the largest increases in BMD of any currently available agent over a 12-month treatment period. All anabolic agents are used for limited periods (2 years for teriparatide and abaloparatide; 12 months for romosozumab) and must be followed by anti-resorptive therapy to consolidate gains.

Chapter 5: Fall Prevention

Risk Factors for Falls and Assessment Tools

Falls in older adults are the product of interacting intrinsic (person-specific) and extrinsic (environmental) factors, and their prevention requires systematic identification and modification of risk factors across multiple domains. The major intrinsic risk factors include: lower limb muscle weakness (particularly hip abductor and knee extensor weakness), gait impairment, balance impairment, vision impairment, cognitive impairment (including both dementia and the attentional consequences of mild cognitive impairment during dual-task conditions), orthostatic hypotension (a fall in systolic BP of ≥ 20 mmHg upon standing), polypharmacy and specific drugs (benzodiazepines, anticholinergics, antidepressants, antihypertensives, and opioids all increase fall risk significantly), history of previous falls, and fear of falling.

Gait speed — the velocity of comfortable-pace walking over a defined distance (typically 4 or 6 meters) — is one of the most powerful and easily measured predictors of fall risk, disability, hospitalization, and mortality in older adults. A gait speed of less than 0.8 m/s (or in some analyses, less than 1.0 m/s) identifies individuals with substantially elevated risk for adverse outcomes. The Timed Up and Go (TUG) test — timing the duration for an individual to rise from a standard chair, walk 3 meters, turn, walk back, and sit down — is widely used as a clinical fall risk screening tool; times exceeding 12–14 seconds indicate elevated fall risk in community-dwelling older adults. The Short Physical Performance Battery (SPPB) combines gait speed, chair stand test (time to complete five chair stands), and balance assessment (side-by-side, semi-tandem, and tandem standing) into a composite score (0–12) that predicts disability and mortality.

Balance assessment tools range from brief clinical screening (the Berg Balance Scale, a 14-item observational scale; the single-leg stance test; the Functional Reach Test) to instrumented force plate analysis (providing center-of-pressure excursion measures during quiet standing, responses to perturbations, and limits of stability) to more complex dynamic balance assessments (the Computerized Dynamic Posturography, which isolates the visual, vestibular, and somatosensory components of balance control by systematically removing or disrupting each sensory input). Clinical fall risk assessment should also include a medication review (identifying and eliminating or reducing high-risk medications where possible), an environmental assessment (identifying and removing tripping hazards, improving lighting, installing grab rails), vision assessment, and cardiovascular assessment (orthostatic blood pressure measurement, cardiac rhythm monitoring where indicated).

Exercise Interventions for Fall Prevention

Exercise is the most evidence-based intervention for fall prevention, with a particularly strong evidence base from systematic reviews and individual trials conducted by the ProFaNE (Prevention of Falls Network Europe) group and subsequent meta-analyses. The key characteristics of fall-preventive exercise identified from this literature are:

Balance challenge is the most critical element. Exercises that progressively challenge balance by reducing the base of support, incorporating dynamic weight shifting, challenging reactive balance responses, and increasing the cognitive demands of balance (dual-task conditions) produce greater improvements in fall risk than exercises that merely strengthen muscles without challenging balance control. Programs with a high proportion of challenging balance exercises (Tai Chi, targeted balance training) produce greater fall rate reductions (30–50%) than programs dominated by general strengthening exercises (10–20% fall reduction).

Muscle strength, particularly of the hip abductors, knee extensors, and ankle dorsiflexors, contributes to fall prevention by improving the strength and speed of protective stepping responses and by supporting joint stability during perturbations. Progressive resistance training that specifically targets these muscle groups improves fall risk scores, though the direct evidence for resistance training alone reducing fall rates is weaker than for balance training.

Duration and adherence: fall prevention exercise programs must be of sufficient duration (at least 3 months, ideally ongoing) and intensity (at least 2 hours per week of balance-challenging exercise) to produce meaningful reductions in fall rates. Home-based programs (such as the Otago Exercise Programme, a progressive home balance and strength program delivered by physiotherapists with follow-up telephone support) are effective and scalable for community-dwelling older adults. Group exercise programs (Tai Chi, group balance classes) have the added benefit of social engagement, which independently supports adherence and wellbeing.

Chapter 6: Exercise Prescription for Osteoporosis and Fracture

Tailoring Exercise for Osteoporosis

The exercise prescription for a person with osteoporosis requires balancing the osteogenic and strength-building benefits of exercise against the risk of fracture from loading vulnerable skeletal sites. The Onco Bone Exercise Guidelines framework and Osteoporosis Canada’s guidelines recommend a progressive exercise program that includes three key components: weight-bearing impact exercise, progressive resistance training, and balance and posture training.

Weight-bearing impact activities — those that generate ground reaction forces substantially exceeding body weight, such as jogging, dancing, step aerobics, and tennis — are the most osteogenic and should be included where fracture risk permits. In individuals with very low BMD (T-score below −3.0), severe vertebral deformity, or prior fracture, the selection of activities requires particular care: high-flexion trunk loading (which places anterior compressive forces on the vertebral bodies — the site of greatest fragility in spinal osteoporosis) must be avoided or modified. Activities specifically contraindicated in severe spinal osteoporosis include: toe touching, sit-ups or crunches, rowing machines, aggressive lumbar flexion stretches, and high-impact activities without adequate trunk support.

Exercise prescription for vertebral fractures is a specialized and clinically challenging area. Vertebral fractures reduce spinal extensor muscle strength through pain inhibition, reflex inhibition (the vertebral fracture reflexively suppresses extensor muscle activity to protect the fracture site from further loading), and mechanical disadvantage (kyphotic posture increases the mechanical demand on the extensors). Progressive spinal extension exercises (prone lying, back extensions in neutral, and eventually resisted extension) are the cornerstone of rehabilitation, targeting the erector spinae and multifidus muscles while avoiding flexion loading. The landmark BEST (Building Better Bones with Exercise) Trial demonstrated that a combined weight training and aerobic exercise program, modified for vertebral fractures, improved femoral neck and lumbar spine BMD and physical function without increasing fracture risk in postmenopausal women with osteoporosis — providing important evidence that appropriately prescribed exercise is safe and beneficial even in this higher-risk population.

Chapter 7: Cartilage Biology and Joint Mechanics

Cartilage Composition and Function

Articular cartilage is a highly specialized tissue covering the articulating surfaces of synovial joints. It is avascular, aneural, and alymphatic — properties that give it excellent compressive mechanical properties (by eliminating compliance from vascular structures within the tissue) but severely limit its intrinsic repair capacity (no blood supply means no delivery of progenitor cells, growth factors, or inflammatory mediators to damaged areas through the conventional wound-healing pathways). These properties make cartilage simultaneously a remarkable biological material and a tissue with profound vulnerability to irreversible damage.

The extracellular matrix of articular cartilage is produced and maintained by chondrocytes — the sole cell type of cartilage, comprising only 2–5% of the tissue volume but responsible for the synthesis and turnover of all matrix components. The matrix consists of approximately 70–80% water (bound within the proteoglycan gel), approximately 15–20% collagen (predominantly type II, organized into an arcade-like fiber arrangement — the Benninghoff arcades — that is tangentially oriented at the surface, transitions to random orientation in the middle zone, and becomes radially oriented in the deep zone approaching the calcified cartilage and subchondral bone), and approximately 5–10% proteoglycans (primarily aggrecan — a large, bottle-brush-shaped proteoglycan with a protein core and numerous attached glycosaminoglycan (GAG) chains — chondroitin sulfate and keratan sulfate — that are highly anionic and attract counterions and water by Donnan osmotic pressure). This abundant intratissue water, held under pressure by the surrounding collagen network and the osmotic pressure of the proteoglycans, is the primary source of cartilage’s remarkable compressive stiffness: when load is applied, water is pressurized and tries to escape from the matrix; the hydraulic pressure generated by this resistance to fluid flow bears the majority of the applied load instantaneously, while the collagen-proteoglycan solid matrix bears load progressively as fluid is slowly expelled. This biphasic mechanical behavior — initially stiff hydraulic response, transitioning to softer solid-phase equilibrium as fluid redistributes — is the mechanistic basis of cartilage’s ability to sustain very high joint contact forces without failure.

Joint Forces and Cartilage Loading

The forces acting on articular cartilage during movement are substantially greater than body weight, because muscles contracting to move and stabilize joints generate forces many times the external load. The knee joint — the most commonly affected joint in osteoarthritis — experiences peak contact forces of 2–3 times body weight during walking, 4–5 times body weight during stair climbing, and 7–8 times body weight during running. These forces are distributed across the articular surface; the contact area and stress distribution vary with joint position and muscle activation, and are profoundly influenced by skeletal alignment, ligamentous integrity, meniscal function, and muscle strength.

The knee adduction moment (KAM) — the external bending moment at the knee in the frontal plane during stance phase of walking — is particularly important in OA biomechanics. During walking, the ground reaction force vector typically passes medial to the knee center, creating an adduction moment that tends to collapse the knee medially. This moment is primarily counteracted by the lateral quadriceps and iliotibial band tension. The KAM determines the proportion of total knee joint force borne by the medial compartment, which typically bears approximately 60–70% of the total joint load. Elevated KAM — associated with varus (bowleg) alignment, obesity, and altered gait mechanics — is the primary mechanical driver of medial compartment OA progression. Interventions targeting KAM reduction — including gait retraining programs (targeting reduced foot progression angle, laterally trunk lean, and step width), lateral wedge insoles, and valgus unloader braces — can reduce medial compartment loading and may slow OA progression in selected patients.

Chapter 8: Osteoarthritis

Pathophysiology of Osteoarthritis

The pathogenesis of OA involves the dysregulation of the normally quiescent chondrocyte, converting it from a maintenance phenotype to a catabolic, hypertrophic phenotype. Key events in OA chondrocyte pathobiology include: increased expression of matrix-degrading enzymes (aggrecanases ADAMTS-4 and ADAMTS-5, which cleave aggrecan GAG chains; collagenases MMP-13 and MMP-1, which degrade type II collagen); decreased expression of matrix-synthesizing genes (type II collagen, aggrecan); upregulation of inflammatory mediators (IL-1beta, TNF-alpha, IL-6, PGE2) that amplify catabolism; and the adoption of a hypertrophic differentiation program resembling endochondral ossification (with expression of type X collagen, MMP-13, and alkaline phosphatase) that culminates in calcification of the deep cartilage zone and eventual cartilage loss. The catabolic drive is initiated and maintained by mechanical injury (impact loading, fatigue loading exceeding cartilage’s repair capacity), inflammatory mediators from the synovium, oxidative stress (ROS generated by mitochondrial dysfunction in aging chondrocytes), advanced glycation end-products on matrix collagen, and reduced availability of trophic signals (IGF-1, TGF-beta) that normally maintain chondrocyte homeostasis.

Subchondral bone plays an active and complex role in OA pathogenesis. In the early stages of OA, subchondral bone may become less dense (bone resorption exceeds formation) — possibly as an adaptation to altered load distribution from early cartilage softening. In established and advanced OA, subchondral bone becomes sclerotic (denser and stiffer), which increases the stress transferred to the overlying cartilage. Bone marrow lesions (BMLs) — regions of increased signal on fluid-sensitive MRI sequences in the subchondral bone — represent areas of trabecular microfracture and associated bone marrow edema; their presence strongly predicts articular cartilage loss and symptom worsening, and they may be a major source of OA pain (stimulating subchondral nociceptors through edema-related pressure and inflammatory mediators). Osteophytes — bony projections at the joint margins — arise from the periosteum and subchondral bone in response to abnormal mechanical loading and elevated TGF-beta; they contribute to joint deformity and range of motion restriction but may represent a partially adaptive response to stabilize the joint by enlarging the contact area.

Clinical Assessment and Exercise Prescription for OA

The clinical assessment of a patient with OA includes: history (joint-specific pain characteristics, functional limitations, impact on quality of life); physical examination (inspection for joint deformity, palpation for joint line tenderness, assessment of range of motion, muscle strength testing, gait analysis); standardized outcome measures (the WOMAC — Western Ontario and McMaster Universities Osteoarthritis Index — which assesses pain, stiffness, and physical function specifically for hip and knee OA on a 24-item questionnaire; the KOOS — Knee Injury and Osteoarthritis Outcome Score — which adds sport/recreation and quality of life subscales); and imaging (plain radiograph for severity staging using the Kellgren-Lawrence (KL) grading system [0 = no OA; 1 = doubtful narrowing and possible osteophytes; 2 = definite osteophytes and possible joint space narrowing; 3 = moderate multiple osteophytes, definite joint space narrowing, and some sclerosis; 4 = large osteophytes, marked narrowing, severe sclerosis, and definite deformity]; MRI for cartilage, meniscal, and bone marrow assessment in appropriate clinical contexts).

Exercise therapy is the most evidence-based non-pharmacological intervention for OA and is recommended as first-line treatment by all major OA clinical guidelines including OARSI, ACR, EULAR, and the 2023 Osteoarthritis Canada guidelines. Aerobic exercise reduces pain and improves function in knee and hip OA through multiple mechanisms: reducing systemic inflammation; improving the nutrition of avascular cartilage (joint loading promotes fluid pumping through cartilage, delivering nutrients by convection); improving cardiovascular fitness and body composition; and reducing pain sensitization through central mechanisms (exercise-induced hypoalgesia mediated by descending inhibitory pathways). Resistance training — targeting the quadriceps and hip muscles — is the most important modality for OA: quadriceps weakness is both a risk factor for OA development and a consequence of established OA (through pain inhibition and disuse atrophy), and quadriceps strengthening reduces dynamic medial compartment loading, improves stability, and reduces pain.

Chapter 9: Rheumatoid Arthritis and Other Joint Diseases

Rheumatoid Arthritis: Pathophysiology

RA affects approximately 1% of the global population, with a female-to-male ratio of approximately 3:1, and typically presents between ages 40 and 60, though it can occur at any age. The disease is predominantly symmetric, affecting the small joints of the hands (MCPs, PIPs) and feet (MTPs) most commonly, with frequent involvement of the wrists, elbows, shoulders, knees, and cervical spine. The characteristic clinical features in active disease include joint pain, swelling, and warmth (reflecting synovitis), morning stiffness exceeding one hour (a hallmark feature reflecting the accumulation of inflammatory fluid during sleep and the stiffness that results from sustained joint inactivity), systemic features (fatigue, weight loss, low-grade fever), and extra-articular manifestations (rheumatoid nodules, interstitial lung disease, pericarditis, peripheral neuropathy, and vasculitis in severe disease).

The pathogenesis of RA involves a complex interplay between genetic susceptibility, environmental triggers (smoking, periodontal disease, and gut dysbiosis have the strongest epidemiological associations), and the autoimmune response. The key genetic risk factor is the HLA-DRB1 shared epitope — a sequence of five amino acids (QKRAA or similar) in the HLA-DRβ1 chain’s peptide-binding groove that is present in HLA-DRB1*04:01, *04:04, *04:05, and other RA-associated alleles. The shared epitope likely increases RA risk by promoting the presentation of autoantigens (particularly citrullinated peptides — proteins with arginine residues converted to citrulline by the enzyme peptidyl-arginine deiminase, PAD — in the inflamed synovium, periodontium, or lung) to T helper cells, initiating autoimmune recognition.

The synovial membrane (synovium) in RA becomes dramatically transformed from its normal two-cell-layer thin structure to a massively hyperplastic, invasive tissue called the pannus (from Latin, meaning “cloth” — reflecting its cloth-like appearance as it grows over the articular surface). The pannus is composed of: synovial fibroblasts (FLS — fibroblast-like synoviocytes) that have acquired an aggressive, semi-transformed phenotype characterized by resistance to apoptosis, anchorage-independent growth, and the production of large quantities of matrix metalloproteinases (MMPs) and cathepsins that invade and degrade cartilage; macrophages that produce TNF-alpha, IL-1beta, IL-6, IL-17, and other pro-inflammatory cytokines that drive the chronic inflammatory cycle; T helper cells (particularly Th17 cells producing IL-17, which powerfully drives RANKL expression and osteoclastic bone erosion); and B cells and plasma cells that produce rheumatoid factor (RF — autoantibodies against the Fc portion of IgG) and anti-citrullinated protein antibodies (ACPA) — antibodies against citrullinated peptides from proteins including vimentin, fibronectin, and alpha-enolase that are among the most specific biomarkers of RA and are detectable in approximately 70% of patients, often years before clinical disease onset.

Treatment and Exercise Prescription for RA

The pharmacological management of RA has been transformed by the development of biologic disease-modifying antirheumatic drugs (bDMARDs) — targeted biological therapies including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab, golimumab), IL-6 inhibitors (tocilizumab, sarilumab), T cell costimulation inhibitor (abatacept), B cell depleting therapy (rituximab), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib). The “treat-to-target” strategy — using standardized disease activity scores (the DAS28, CDAI, or SDAI) to guide treatment intensification with the goal of achieving remission or low disease activity — has dramatically improved outcomes, with the majority of patients now achieving good disease control when treated according to current guidelines.

Exercise is a cornerstone of RA management, recommended by EULAR guidelines as a key component of the non-pharmacological management plan. Historically, exercise was thought to worsen joint inflammation in RA — a misconception that persisted for decades and caused patients to be advised to rest joints during disease activity. This advice was incorrect and harmful: long-term physical inactivity in RA accelerates muscle wasting (RA cachexia), cardiovascular disease risk (already substantially elevated in RA due to systemic inflammation), bone loss (inflammatory cytokines directly drive RANKL-mediated bone erosion), and functional decline. Randomized trials of aerobic exercise and resistance training in RA patients — including during periods of moderate disease activity — demonstrate significant improvements in cardiovascular fitness, muscle strength, fatigue, depression, and quality of life, without significantly increasing joint inflammation or radiographic progression.

Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood, encompassing a heterogeneous group of arthritides that begin before age 16, last at least 6 weeks, and have no identifiable cause. The seven subtypes recognized by the International League of Associations for Rheumatology (ILAR) classification — systemic, oligoarticular, polyarticular RF-negative, polyarticular RF-positive, psoriatic, enthesitis-related, and undifferentiated — differ in their clinical manifestations, genetics, associated conditions, prognosis, and treatment. Nutrition and exercise are important but frequently neglected aspects of JIA management.

Children with JIA are at high risk for growth disturbance (particularly local overgrowth or undergrowth of bones adjacent to inflamed joints, and generalized growth suppression from systemic inflammation and glucocorticoid treatment), osteoporosis (from systemic inflammation, reduced physical activity, and glucocorticoid exposure), and sarcopenia (from inflammation-mediated muscle catabolism and activity limitation). Regular, appropriately modified physical activity — avoiding high-impact activities on severely inflamed joints while maintaining overall fitness, muscle strength, and joint range of motion — is essential for mitigating these complications and supporting normal childhood development. Exercise prescription must be individualized based on the current distribution of joint involvement, disease activity, pain, and the child’s development stage.

Gout, Spondyloarthropathies, and Chronic Pain

Gout is the most common inflammatory arthropathy in men and a rapidly growing problem worldwide, driven by rising prevalence of obesity, hypertension, chronic kidney disease, and diuretic use — all of which increase serum urate. Gout is a monosodium urate (MSU) crystal deposition disease: when serum uric acid exceeds the solubility limit (approximately 360–420 μmol/L), MSU crystals precipitate in the synovium, soft tissues, and kidneys, triggering intense IL-1beta-mediated inflammation (through NLRP3 inflammasome activation by MSU crystals in macrophages). Nutritional management of gout includes reducing purine-rich food intake (particularly red meat, organ meats, and shellfish), reducing fructose intake (which drives hepatic uric acid production), limiting alcohol (which reduces urate excretion), and maintaining adequate hydration. The Mediterranean diet is associated with lower serum urate and reduced gout risk in observational studies.

Seronegative spondyloarthropathies — including ankylosing spondylitis (AS, now preferentially termed axial spondyloarthritis), psoriatic arthritis (PsA), reactive arthritis, and enteropathic arthropathy — share several characteristics: predominant axial involvement (spinal and sacroiliac joint inflammation), enthesitis (inflammation at the sites of tendon, ligament, and joint capsule attachment to bone), negative RF and ACPA, and strong genetic association with HLA-B27. Ankylosing spondylitis — progressive inflammatory disease of the axial skeleton producing spinal fusion — is particularly relevant to exercise prescription because spinal mobility preservation is a major treatment goal and regular exercise (specifically extension, rotation, and breathing exercises) is the primary non-pharmacological intervention.

Chronic pain management — particularly in the context of musculoskeletal conditions — increasingly incorporates an understanding of central sensitization — the amplification of pain processing at the spinal cord and brain level that occurs when peripheral nociceptive input is sustained. Central sensitization is characterized by allodynia (pain from non-painful stimuli), hyperalgesia (exaggerated pain from normally painful stimuli), and widespread pain extending beyond the anatomically injured region. For exercise physiologists working with patients with chronic musculoskeletal pain, understanding central sensitization is critical: graduated exercise programs must be designed to gradually increase pain threshold and reduce fear-avoidance behavior, using a biopsychosocial model that addresses the psychological, social, and neurobiological contributors to pain alongside the physical rehabilitation components.